Gabay Avraham 4

What Happened

• Gabay Avraham, Chief Financial Officer of Oramed Pharmaceuticals (ORMP), had 19,000 performance stock units (PSUs) convert into 19,000 shares of common stock on January 22, 2026. The shares were issued upon achievement of the PSU performance condition and were received for no cash consideration.

Key Details

• Transaction date: January 22, 2026.
• Transaction type: Conversion/settlement of PSUs (reported as derivative exercise/conversion, code M); 19,000 shares acquired at $0.00.
• Amounts: 19,000 PSUs converted to 19,000 common shares; no cash paid.
• Shares owned after transaction: not specified in the filing.
• Footnotes: F1 notes the PSUs granted on 12/31/2025 vested upon achieving a specified share-price target; F2 clarifies each PSU entitled the holder to one share upon performance achievement.
• Filing: Form 4 filed on January 29, 2026 (the filing date is seven days after the transaction date).

Context

• This was an award/vesting event (PSU settlement), not an open-market purchase or sale; it reflects compensation tied to performance criteria rather than an active buy/sell decision by the insider. No immediate sale of the received shares was reported in this filing.